Trending: Novo Nordisk Faces Senate Over Ozempic, Wegovy Pricing
15:02 ET -- Novo Nordisk is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The Danish drugmaker's CEO Lars Jorgensen challenged Medicare's negotiating of prescription drug prices during testimony before a Senate committee. Jorgensen defended the pricing of his company's diabetes and weight-loss drugs Ozempic and Wegovy, which he said are set during negotiations with insurers and pharmacy-benefit managers. Ozempic is likely eligible to be included in next year's price negotiations between Medicare and drugmakers, said Novo Nordisk in written testimony. Dow Jones & Co. owns Factiva. (jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
September 24, 2024 15:19 ET (19:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States